Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatocellular Carcinoma
100%
Overall Survival
25%
Advanced Hepatocellular Carcinoma
25%
Sorafenib
17%
Atezolizumab
16%
Immune Checkpoint Inhibitors
15%
Unresectable Hepatocellular Carcinoma (uHCC)
13%
Progression-free Survival
12%
Hepatocellular Carcinoma Patient
11%
Systemic Therapy
9%
Bevacizumab
9%
95% Confidence Interval
7%
Insulin-like
7%
Growth Factors
6%
Tumor
6%
Hepatitis C Virus
6%
Cirrhosis
6%
Nivolumab
6%
Thymoquinone
6%
Phase I Trial
6%
Neoadjuvant Therapy
6%
Liver
5%
Adverse Events
5%
Intrahepatic Cholangiocarcinoma (iCCA)
5%
Liver Transplantation
5%
Median Overall Survival
5%
Hazard Ratio
5%
Partial Response
5%
Phase II Trial
5%
Medicine and Dentistry
Hepatocellular Carcinoma
88%
Overall Survival
23%
Diseases
13%
Neoplasm
13%
Malignant Neoplasm
12%
Cholangiocarcinoma
12%
Sorafenib
11%
Immune Checkpoint Inhibitor
10%
Progression Free Survival
9%
Immunotherapy
9%
Systemic Therapy
7%
Liver Transplantation
7%
Radiation Therapy
7%
Bevacizumab
6%
Atezolizumab
6%
Genetics
6%
Somatomedin C
6%
Tumor
5%
Liver Cirrhosis
5%
Neoadjuvant Therapy
5%
Liver Cancer
5%
Transcatheter Arterial Chemoembolization
5%
Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
56%
Sorafenib
13%
Malignant Neoplasm
12%
Bevacizumab
11%
Atezolizumab
10%
Overall Survival
10%
Adverse Event
8%
Progression Free Survival
7%
Immunotherapy
7%
Neoplasm
6%
Diseases
6%
Immune Checkpoint Inhibitor
6%
Thymoquinone
5%